Tuesday, October 4, 2022


Biotechnology News Magazine

VIRTUALMAN and Hughes Biotechnology, Speed Up and Optimize R&D Processes with Innovative Technology

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

March 8, 2021

VIRTUALMAN and Hughes Biotechnology, (Taiwanese biotechnology companies) are paying close attention to this shift in the trend and revolutionizing R&D processes.

In 2020, artificial intelligence (AI) company VIRTUALMAN guided four pharmaceutical entities to a more streamlined hit compound screening process excelling at toxicity and bioavailability in-silico predictions. The cloud platform behind this, powered by customizable AI models, is capable of generating over a thousand compounds with higher potential concerning multiple endpoints such as toxicity and absorption, accomplishable in a short span of just three weeks. Without needing to economize at the cost of quality, their AI platform excels at multitasking the elements of the hit-to-lead process.

Despite the development of in-silico tools for decades, it has still been hard for drug companies to analyze novel compounds due to the limitations of current statistical models. The secret behind VIRTUALMAN’s drug development mastery lies in its powerful algorithms; a system generated by the company’s team of dedicated computer scientists that effectively produces highly accurate and explainable results.

Working in tandem with them is a team of chemists experienced in novel drug development. This comprehensive expertise allows VIRTUALMAN to serve small molecule drug companies better with a thorough understanding of their problems. By identifying relevant and specific hit compounds from the beginning, the number of compounds tested is reduced. The drug development process is thus accelerated, economized, and produces safer hit compounds.

VIRTUALMAN CEO Tien Yun-cheng acclaims the advantages of AI technology. “The benefits of leveraging AI into R&D processes are widely recognized in the pharmaceutical industry. Effective AI solutions are provided to save time in experiments and accelerate small molecule drug development. VIRTUALMAN’s all-in-one services can be easily adopted by companies lacking AI expertise. Our sophisticated cloud platform enables the integration of clients’ existing processes and new technology.”

Hughes Biotechnology enhances the effectiveness of health supplements

Unlike the aforementioned company that focuses on drug-development, Hughes Biotechnology is one that develops active ingredients used in fuss-free supplements. Its breakthrough strategy has improved the solubility and bioavailability of nutraceuticals. Having won the 2020 Ministry of Science and Technology Academia-Industry Collaboration Award, Hughes Biotechnology is expected to navigate next-generation nutraceutical ingredients with its unique proprietary biological technique “RenoSorb™”.

RenoSorb™ greatly enhances the solubility of plant-based active ingredients. Instead of excipients or nanoparticle technology, the company applies functional groups through a unique bioprocess to a broad range of active substances. Thus, ingredients are water-soluble as opposed to water-dispersible. Water-dispersible products are low in purity and not composed of 100% food-grade components, whereas the opposite holds for water-soluble products as demonstrated by RenoFlavone™.

RenoFlavone™ (next-generation isoflavone) is the first product developed in a breakthrough using RenoSorb™. The technique has been scientifically proven to increase the aqueous solubility and bioavailability of a raw ingredient by 100,000 and 3.7 times respectively, maximizing the ingredient’s benefits across nutraceuticals, pharmaceuticals, and skincare.

Additionally, Hughes Biotechnology has also launched RenoCidin™ and RenoSage™ (next-generation hesperetin and luteolin respectively). Such products can be involved in a broad array of applications like health drinks, jellies, and lotions, just to name a few. Other ingredients in the pipeline include curcumin, silymarin, rutin, quercetin, and resveratrol.

Presently, Hughes Biotechnology is collaborating with global companies from the U.S. and Australia. Hughes Biotechnology is on the lookout to expand their collaborations with appropriate partners on a larger scale internationally in a movement to commercialize their products, as well as co-develop new ones.

“We at Hughes believe that our innovative technology is a breakthrough, and our assets are perfectly aligned with the rising trend toward broadly using plant-based ingredients to address healthcare needs,” says Dr. James Hsu, research director of Hughes Biotechnology.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine